Editas Medicine, Inc. announced recent achievements. In Vivo Gene Edited Medicines: EDIT-101 for Leber Congenital Amaurosis 10 (LCA10). IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data; concurrently enrolling patients in adult high-dose cohort. Editas Medicine has completed dosing of the adult mid-dose cohort and, following the endorsement by the Independent Data Monitoring Committee (IDMC), has opened enrollment for the first pediatric cohort. The Company is also enrolling patients in the adult high-dose cohort. Completion of dosing for both cohorts is expected in the first half of 2022. Initial clinical data planned for the International Symposium on Retinal Degeneration (RD2021) in September 2021. Initial EDIT-101 clinical data is planned for presentation at the International Symposium on Retinal Degeneration (RD2021) in September 2021 by one of the study’s Principal Investigators. Data will include patient safety assessments and a preliminary analysis of secondary endpoints relating to signals of gene editing and clinical benefit. The presentation will cover cumulative data from patients in the adult low-dose and mid-dose cohorts. As required by the trial protocol, all patients are monitored every three months for the first year and at various timepoints for another two years.EDIT-301 for Sickle Cell Disease: On track to dose first patient in RUBY trial by year-end. The Company is developing EDIT-301 as a potentially best-in-class medicine to treat sickle cell disease. Editas Medicine uses a proprietary engineered CRISPR/Cas12a ribonucleoprotein (RNP) to edit the HBG1/2 promoter mimicking a benign and naturally occurring human fetal hemoglobin mutation. This site is a naturally validated location, as patients with Hereditary Persistence of Fetal Hemoglobin (HPFH) harbor the sickle cell mutation but do not exhibit symptoms of the disease. The Company believes that targeting this site is a more effective approach with better long-term safety than editing the BCL11A enhancer. The Phase 1/2 RUBY trial for the treatment of sickle cell disease is currently screening study participants. The Company remains on track to begin patient dosing in the RUBY trial by the end of 2021. Health Canada approved CTA for trial initiation in Canada. The Company received an approved clinical trial application (CTA) from Health Canada for the RUBY trial of EDIT-301, expanding the number of potential clinical sites for the study. This is Editas Medicine’s first CTA approval. Preclinical data presented at EHA supports EDIT-301 as potential best-in-class treatment for sickle cell disease. Editas Medicine presented preclinical data on EDIT-301 at the European Hematology Association Congress (EHA). The data demonstrated therapeutically relevant levels of fetal hemoglobin (HbF) in red blood cells derived from sickle cell patient CD34+ cells, as well as a reduction of sickling and improved rheological behavior. Cells were edited with a novel, highly active and specific, Editas-engineered AsCas12a enzyme with no detection of off-target editing. These data further support EDIT-301 for clinical development use. EDIT-301 for Beta-Thalassemia: On track to file IND by year-end for a differentiated treatment for beta-thalassemia. The Company remains on track to file an investigational new drug application for EDIT-301 for the treatment of beta-thalassemia by the end of 2021. Cellular Therapy: Edited iPSC NK (iNK) Cell Medicines to Treat Solid Tumors. Advancing preclinical studies towards multiplexed edited product. Editas Medicine is continuing to advance preclinical studies for a highly differentiated, iPSC-derived natural killer (NK) cell medicine. The Company is optimizing editing configurations for corresponding clinical targets. The finalized product candidate will include multiple edits, for which the Company has previously demonstrated high levels of multiplexed editing efficiency.